The company has recently achieved successful site audits from various esteemed pharmaceutical companies, including local entities such as Weizhi Pharmaceutical, Amphastar Nanjing Pharmaceuticals, and Hiray Pharma, as well as international counterparts like Hetero and Azico in India. The audits specifically covered projects involving Tetrabenzyl pyrophosphate (CAS: 990-91-0), (1R,4S,4aR,9aS)-rel-1,4,4a,9a-Tetrahydro-4a-methyl-1,4-methanoanthracene-9,10-dione (CAS: 97804-50-7), Dibenzyl phosphate, 4-DifluoroMethoxy-3-hydroxybenzaldehyde (CAS: 151103-08-1; Roflumilast intermediate), and various other initiatives.